Professor Jonathan Edwards is an Emeritus Professor of Connective Tissue Medicine at University College London (UCL) in the UK. Professor Edwards was instrumental in the discovery of the use of B-cell depletion therapy (Rituximab) to treat rheumatoid arthritis.
B-cell Depletion ME/CFS Research
Professor Edwards became interested in the possible use of Rituximab to treat ME/CFS after attending the Invest in ME International ME Conference in May 2013 and subsequently agreed to advise on and lead the effort.
Open Letter to The Lancet
Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. The first, written in 2015, was sign by Dr. Edwards and 5 of his colleagues. In 2016, thirty-six additional colleagues in the ME/CFS field, signed the second letter.
- 13 November 2015, An open letter to Dr. Richard Horton and The Lancet
- 10 February 2016, An open letter to The Lancet, again - Virology blog
Publications Related to ME/CFS
- 2017, PACE team response shows a disregard for the principles of science in Journal of Health Psychology
- 2016, The biological challenge of myalgic encephalomyelitis/chronic fatigue syndrome: a solvable problem, Editorial by Jonathan C.W. Edwards, Simon McGrath, Adrian Baldwin, Mark Livingstone & Andrew Kewley
Talks & Interviews
- 30 May 2014, Keynote Speaker at the 9th Invest in ME International ME Conference - DVD available
- 3 Sept 2013, Interview: Professor Jonathan Edwards on the UK Rituximab trial
- B cell depletion: an effective therapy in rheumatoid arthritis
- UK rituximab Trial - Statements By Professor Jonathan Edwards and Invest in ME - July 2013
- Phoenix Rising Adds Two New Board Members
- Jonathan Edwards
- Edwards, J.C.W., McGarth, S., Baldwin, A., Livingstone, M., Kewley, A. (2016). The biological challenge of myalgic encephalomyelitis/chronic fatigue syndrome: a solvable problem. Fatigue: Biomedicine, Health & Behavior 4 (2):63-69. doi: 10.1080/21641846.2016.1160598